^
    Back
    Association details:
    Biomarker:ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

    Excerpt:
    ...Characterization of Anaplastic Lymphoma Kinase fusion partner on DNA extracted from tissue biopsy and on cell-free nucleic acid (cfNA) (both cfDNA and cfRNA) extracted from plasma sample....
    Trial ID:
    ALNEO
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Anticancer Drugs
    Title:

    Neoadjuvant alectinib in locally advanced lung adenocarcinoma with anaplastic lymphoma kinase rearrangement: case series and literature review

    Published date:
    01/24/2023
    Excerpt:
    ...a 64-year-old man with no history of smoking who was diagnosed with the clinical stage as IIIB, with ALK fusion-positive. Chest-enhanced computed tomography (CT) revealed marked regression and achieved partial response (PR) incorporated with grade 3 interstitial pneumonia after 44 days of alectinib neoadjuvant therapy....The pathological assessment was a pathologic complete response(pCR).
    DOI:
    10.1097/CAD.0000000000001507